title: [Anti-tumor effects induced by the DNA vaccine coding human and mouse soluble VEGFR2].
abstract: OBJECTIVE
  To develop a novel anti-angiogenesis strategy based on a DNA vaccine coding both human and mouse soluble VEGFR2.
  
  
  METHODS
  The gene fragments coding human and mouse sVEGFR2 were amplified with PCR and cloned into pVITRO2 to generate pVITRO2-hm-sVEGFR2 recombinant. The in vitro VEGF blocking effect of the pVITRO2-hm-sVEGFR2 expression products on HUVEC cells were evaluated. The anti-tumor effect of pVITRO2-hm-sVEGFR2 was studied in mouse B16 model. The microvessels were stained by using CD31 antibody.
  
  
  RESULTS
  The co-expressing vector pVITRO2-hm-sVEGFR2 was constructed successfully, confirmed by the restriction endonuclease digestion and sequencing. The expressing products of pVITRO2-hm-sVEGFR2 could obviously block the function of VEGF on promoting the proliferation of HUVEC in vitro. The tumor growth in mice was also significantly inhibited by pVITRO2-hm-sVEGFR2 expression. CD31 staining demonstrated that the microvessel density obviously decreased in tumor tissues treated with pVITRO2-hm-sVEGFR2. Both anti-tumor and anti-angiogenesis effects of pVITRO2-hm-sVEGFR2 were stronger than that of plasmids which coding only human or mouse sVEGFR2.
  
  
  CONCLUSIONS
  pVITRO2-hm-sVEGFR2 could be a novel DNA vaccine for the anti-tumor therapy by inhibiting angiogenesis.
authors.affiliation: State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Lu
authors.initials: L
authors.lastname: Jin
authors.forename: Yu-Wei
authors.initials: YW
authors.lastname: Zhao
authors.forename: Zhi-Mian
authors.initials: ZM
authors.lastname: Li
authors.forename: Cheng-Jian
authors.initials: CJ
authors.lastname: Zhao
authors.forename: Xiao-Fei
authors.initials: XF
authors.lastname: Wang
authors.forename: Ling
authors.initials: L
authors.lastname: Zhang
authors.forename: Han-Shuo
authors.initials: HS
authors.lastname: Yang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology*; D002460:Cell Line; D004926:Escherichia coli / Q000235:genetics / Q000378:metabolism; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D008546:Melanoma, Experimental / Q000628:therapy; D051379:Mice; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology*; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics / Q000276:immunology*
chemical_list: D020533:Angiogenesis Inhibitors; D019496:Cancer Vaccines; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D040301:Vascular Endothelial Growth Factor Receptor-2